IDEAYA is employing a translational platform based on cutting-edge technologies for discovery, validation and clinical development of biomarkers in parallel with novel therapeutics. Biomarker-enabled translational approaches help enhance patient outcomes – by identifying patients likely to respond to particular therapies and by providing clinical insights based on extent of target modulation.
Diagnostic biomarkers include predictive, prognostic and resistance biomarkers. For a particular cancer indication, or potentially pan-indication, predictive biomarkers help select for patients most likely to benefit from a drug. Prognostic biomarkers provide information about a patient’s overall outcome, independent of a particular therapy. Resistance biomarkers enable clinical decisions for potential combinations and/ or next-line therapies.
Pharmacodynamic biomarkers are used both in pre-treatment and post-treatment testing to confirm and understand the extent of target modulation. In addition to providing biological proof-of-activity, such information can inform clinical decision making – e.g., dosing amounts and/or schedules.
Companion diagnostics (CDx) are diagnostic products intended for launch with a therapeutic drug. CDx products help support clinical decision-making as a diagnostic or pharmacodynamic biomarkers.
IDEAYA’s translational platform includes in-house capabilities coupled with strategic networks and partnerships for discovery, validation and clinical development of biomarkers. IDEAYA is applying its biomarker-enabled translational platform across several mechanistic approaches based on cancer biology, including targeted therapies that directly target tumor genomic susceptibilities, breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism.